ResMed Inc. (NYSE:RMD) Stock Holdings Increased by Achmea Investment Management B.V.

Achmea Investment Management B.V. raised its stake in ResMed Inc. (NYSE:RMD - Free Report) by 6.1% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 237,797 shares of the medical equipment provider's stock after acquiring an additional 13,703 shares during the period. ResMed accounts for about 0.8% of Achmea Investment Management B.V.'s investment portfolio, making the stock its 23rd biggest holding. Achmea Investment Management B.V. owned about 0.16% of ResMed worth $53,231,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Board of the Pension Protection Fund boosted its position in shares of ResMed by 15.0% during the first quarter. Board of the Pension Protection Fund now owns 4,600 shares of the medical equipment provider's stock worth $1,030,000 after buying an additional 600 shares during the period. Robeco Institutional Asset Management B.V. lifted its stake in ResMed by 6.9% during the first quarter. Robeco Institutional Asset Management B.V. now owns 77,442 shares of the medical equipment provider's stock valued at $17,335,000 after purchasing an additional 4,983 shares during the last quarter. Terra Nova Asset Management LLC grew its position in ResMed by 0.7% in the first quarter. Terra Nova Asset Management LLC now owns 7,950 shares of the medical equipment provider's stock worth $1,780,000 after buying an additional 52 shares during the last quarter. Golden State Wealth Management LLC increased its holdings in shares of ResMed by 384.8% in the first quarter. Golden State Wealth Management LLC now owns 160 shares of the medical equipment provider's stock valued at $36,000 after buying an additional 127 shares in the last quarter. Finally, Moran Wealth Management LLC acquired a new stake in shares of ResMed during the first quarter worth $10,574,000. 54.98% of the stock is currently owned by institutional investors.

ResMed Price Performance

NYSE:RMD opened at $256.49 on Friday. The firm's fifty day moving average price is $244.15 and its two-hundred day moving average price is $235.33. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.41 and a quick ratio of 2.49. The company has a market cap of $37.61 billion, a P/E ratio of 28.79, a P/E/G ratio of 1.78 and a beta of 0.78. ResMed Inc. has a one year low of $186.22 and a one year high of $263.05.

ResMed (NYSE:RMD - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $2.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.36 by $0.01. ResMed had a return on equity of 25.67% and a net margin of 26.15%. The business had revenue of $1.29 billion during the quarter, compared to analysts' expectations of $1.28 billion. During the same period in the previous year, the company posted $2.13 earnings per share. The firm's revenue for the quarter was up 7.9% compared to the same quarter last year. Equities analysts expect that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, June 12th. Stockholders of record on Thursday, May 8th were issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 0.83%. The ex-dividend date was Thursday, May 8th. ResMed's dividend payout ratio (DPR) is currently 23.79%.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on RMD. Morgan Stanley set a $286.00 price objective on ResMed and gave the stock an "overweight" rating in a research note on Tuesday, May 20th. KeyCorp set a $274.00 price target on shares of ResMed in a research note on Thursday, April 24th. UBS Group lowered their price target on ResMed from $290.00 to $285.00 and set a "buy" rating on the stock in a report on Thursday, April 24th. Royal Bank Of Canada lifted their price objective on ResMed from $247.00 to $255.00 and gave the stock a "sector perform" rating in a research note on Thursday, April 24th. Finally, JPMorgan Chase & Co. boosted their target price on shares of ResMed from $286.00 to $290.00 and gave the stock an "overweight" rating in a research report on Thursday, April 24th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $259.33.

Insider Buying and Selling

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of the firm's stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $219.74, for a total value of $439,480.00. Following the completion of the sale, the director now directly owns 73,218 shares in the company, valued at approximately $16,088,923.32. This trade represents a 2.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michael J. Farrell sold 8,009 shares of the stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $251.21, for a total value of $2,011,940.89. Following the completion of the transaction, the chief executive officer now owns 455,503 shares in the company, valued at approximately $114,426,908.63. The trade was a 1.73% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,132 shares of company stock worth $7,075,837 in the last ninety days. Company insiders own 0.71% of the company's stock.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.

Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.